Invokana sales?

Invokana (canagliflozin) is a Janssen product. If you want current sales data, please tell me:
- Global or U.S. sales?
- Which year(s) you want (e.g., 2023, 2024, trailing 4 quarters)?

Short context: Invokana’s sales grew after launch in 2013 and peaked in the mid-2010s, but have declined in recent years due to competition from other SGLT2 inhibitors and safety-label updates (notably the lower-limb amputation signal). Exact figures vary year by year, and the latest numbers are usually reported in Johnson & Johnson/Janssen annual/financial reports or industry data services.

If you specify the timeframe, I can give you the latest available figure or a quick trend summary.